Clinical trial reveals positive results for treating children with rare gliomas
Tafinlar and Mekinist led to a 56% overall response rate in children with BM-HGG
Read More
Tag: trametinib
NHS green light for Novartis skin cancer combo
The NHS now has three months to ensure that Novartis’ combination therapy dabrafenib/trametinib is routinely available to eligible skin cancer patients, after cost regulators published guidance backing funds for the treatment.
Read More
Breakthrough badge for Novartis’ skin cancer combo
A targeted combination therapy being developed by Novartis as adjuvant treatment for patients with a certain type of melanoma has been assigned breakthrough designation in the US.
Read More
BMS, Novartis to test Mekinist/Opdivo combo
Novartis and Bristol-Myers Squibb have signed a clinical research pact to investigate the safety, tolerability, and efficacy of combining their respective drugs Mekinist and Opdivo.
Read More
EU OKs Novartis’ Tafinlar/Mekinist combo for lung cancer
European regulators have expanded the scope of Novartis’ Tafinlar/Mekinist combination to include the treatment of patients with a certain form of lung cancer.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
